Key Details
Price
$1.14Annual ROE
-48.93%Beta
1.35Events Calendar
Next earnings date:
Apr 04, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Apr 04, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
05 Apr '24 Piper Sandler
Neutral05 Apr '24 Chardan Capital
Buy14 Dec '23 B of A Securities
Underperform07 Aug '23 Chardan Capital
Buy11 May '23 Chardan Capital
Buy07 Dec '22 Piper Sandler
Overweight07 Dec '22 Chardan Capital
Buy26 Apr '21 Piper Sandler
Overweight26 Apr '21 Oppenheimer
Outperform26 Apr '21 JP Morgan
UnderweightMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Achilles Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
ACHL
globenewswire.com14 November 2024
– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –
Achilles Therapeutics to Present at Upcoming Conferences
ACHL
GlobeNewsWire12 June 2023
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June:
3 Stocks With 1,000% Upside Potential
ACHL
InvestorPlace21 May 2023
If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high.
FAQ
- What is the primary business of Achilles Therapeutics?
- What is the ticker symbol for Achilles Therapeutics?
- Does Achilles Therapeutics pay dividends?
- What sector is Achilles Therapeutics in?
- What industry is Achilles Therapeutics in?
- What country is Achilles Therapeutics based in?
- When did Achilles Therapeutics go public?
- Is Achilles Therapeutics in the S&P 500?
- Is Achilles Therapeutics in the NASDAQ 100?
- Is Achilles Therapeutics in the Dow Jones?
- When was Achilles Therapeutics's last earnings report?
- When does Achilles Therapeutics report earnings?
- Should I buy Achilles Therapeutics stock now?
What is the primary business of Achilles Therapeutics?
Achilles Therapeutics is a biotechnology company focused on developing personalized cancer therapies. They use advanced genetic techniques to identify and target unique tumor mutations, aiming to create effective treatments for patients with solid tumors, particularly in lung cancer. Their innovative approach seeks to improve patient outcomes in oncology.
What is the ticker symbol for Achilles Therapeutics?
The ticker symbol for Achilles Therapeutics is NASDAQ:ACHL
Does Achilles Therapeutics pay dividends?
No, Achilles Therapeutics does not pay dividends
What sector is Achilles Therapeutics in?
Achilles Therapeutics is in the Healthcare sector
What industry is Achilles Therapeutics in?
Achilles Therapeutics is in the Biotechnology industry
What country is Achilles Therapeutics based in?
Achilles Therapeutics is headquartered in United Kingdom
When did Achilles Therapeutics go public?
Achilles Therapeutics's initial public offering (IPO) was on 31 March 2021
Is Achilles Therapeutics in the S&P 500?
No, Achilles Therapeutics is not included in the S&P 500 index
Is Achilles Therapeutics in the NASDAQ 100?
No, Achilles Therapeutics is not included in the NASDAQ 100 index
Is Achilles Therapeutics in the Dow Jones?
No, Achilles Therapeutics is not included in the Dow Jones index
When was Achilles Therapeutics's last earnings report?
Achilles Therapeutics's most recent earnings report was on 14 November 2024
When does Achilles Therapeutics report earnings?
The next expected earnings date for Achilles Therapeutics is 4 April 2025
Should I buy Achilles Therapeutics stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions